Navigation Links
PET scan with [11C]erlotinib may provide noninvasive method to identify TKI-responsive lung tumors
Date:7/5/2011

A non-invasive PET imaging technique may identify lung cancers that respond best to tyrosine kinase inhibitors (TKIs), allowing doctors to better select patients for personalized therapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC).

"As more and more therapeutic agents are becoming available for non-small cell lung cancer therapy, selecting the best drug for each individual patient becomes increasingly challenging," said principal investigator Dr. Idris Bahce, of VU University Medical Center in Amsterdam, the Netherlands. "Predictive markers may offer guidance in personalizing therapy."

One marker that predicts tumor response to TKIs is the activating mutation of the epidermal growth factor receptor (EGFR) gene of the tumor cells, Dr. Bahce said. But it's not easy to obtain adequate tumor tissue from the patient for DNA analysis to determine whether the mutation exists.

In the study, non-small cell lung cancer (NSCLC) patients underwent PET (positron emission tomography) scans using radiolabeled erlotinib, a TKI.

"We found that patients who had an activating EGFR mutation also had an increased tracer uptake and were more sensitive to treatment with erlotinib as compared to those who did not have this mutation," Dr. Bahce said. "This is an important finding, as it indicates that this new imaging PET technique may be a non-invasive predictive marker that identifies NSCLC patients who benefit from treatment with TKIs."

Ten NSCLC patients, five with wild-type EGFR and five with activating EGFR mutations -- determined by DNA sequencing on tumor tissue -- were included in the study. Each was scanned twice using a procedure that included a low-dose computed tomography (CT) scan, a 10 minute [15O]water dynamic PET scan and a one-hour [11C]erlotinib dynamic PET scan.

Tumor uptake of [11C]erlotinib was significantly higher in the mutated group (median uptake (VT) = 1.70; range 1.33-2.30) than in the wild-type group (median uptake (VT) = 1.18; range, 0.75-1.34; p = 0.03). This difference was not due to differences in tumor perfusion. Tracer [11C]erlotinib uptake correlated with tumor response to subsequent erlotinib treatment, as only high-uptake tumors responded to treatment.


'/>"/>

Contact: Renee McGaw
renee.mcgaw@ucdenver.edu
31-205-493-413
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. New Website Provides Counselors with Instant Help for Troubled Kids
2. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
3. Medical Transcription Services and EHR Provider MxSecure Launches New Enhanced Website with Goal of Improved Physician Productivity
4. Providence Service Corporation Relocates Corporate Headquarters to Downtown Tucson
5. Keenan Chief Strategy Officer Selected to Join Editorial Board of Payers & Providers
6. DavisPTnetwork Partners with the New York Physical Therapy Association to Provide Online Continuing Education
7. Rhode Island Settlement Reflects Homeowner Liability for Serving Alcohol to Those Under 21, Says Providence Lawyer Mark Gemma
8. Southridge LLC Provides Equity Capital Through Private Agreement with PuraMed Bioscience
9. MarquisNet Co-Location Agreement with MessageBroadcast Helps Message Delivery Provider Expand World-Class Network
10. Top Raleigh Dentist Robert Williamson Designated A Preferred Invisalign Provider
11. Save the Children Provides Songs with Lifesaving Health and Nutrition Advice to Haitian Radio Stations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... , ... The Case Management Society of America (CMSA) will install six new ... membership has elected their upcoming President-Elect, Secretary, Treasurer and two Directors to serve on ... Advisory position has also been added to the BOD, per an appointment made by ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek ... to pursue the recent RNA methylation “gold rush” with their established portfolio of ... newfound characteristics of N6-methyladenosine, or m6A , RNA methylation has received a ...
(Date:3/27/2017)... Foothill Ranch, California (PRWEB) , ... March 27, 2017 , ... ... company’s commitment to its customers. First National Capital has added 10 new sales professionals ... to grow its sales positions by 15 additional new hires over the course of ...
(Date:3/27/2017)... RICHEY, Fla. (PRWEB) , ... March 27, 2017 ... ... drug overdose deaths soared 167%,(1) with opioids alone responsible for over 33,000 of ... Kevin McCarty has sponsored Assembly Bill (AB) 1512, which proposes a tax on ...
(Date:3/25/2017)... ... March 25, 2017 , ... Norland at Swissray is pleased to announce the ... subjects. The ELITE DXA has an active scan window, which is more than double ... fit in the scan area could not undergo an accurate total body bone density or ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... -- A new survey from the American Association ... Program (CBP) significantly reduced beneficiary choice and access to ... forces beneficiaries to switch to unfamiliar or unsuitable testing ... AADE,s survey is the latest in a continuous ... the inherent problems with the CBP. Last year, a ...
(Date:3/27/2017)... YORK , March 27, 2017 FinancialBuzz.com ... Based ... adult use in states where cannabis is legal will generate $655 ... million will be from cannabis specific taxes, such as ... $96 million will be earned from state sales taxes that are ...
(Date:3/27/2017)... BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... AGI-134, an immunotherapy for the treatment of multiple cancers, obtained ... featured at the upcoming American Association for Cancer Research ... to be held on April 1-5, 2017. ... An abstract titled ...
Breaking Medicine Technology: